652
Participants
Start Date
October 31, 2007
Primary Completion Date
March 31, 2009
Study Completion Date
April 30, 2009
Lu AA24530
per oral, once daily for 6 weeks
Duloxetine
per oral, once daily for 6 weeks
Placebo
per oral, once daily for 6 weeks
IN007, Chennai
AT001, Vienna
NO004, Fredrikstad
PH002, Las Piñas
NO001, Hamar
BE003, Diest
AU004, Epping
AU006, Malvern
AU003, Dandenc
NO003, Skien
AU002, Brisbane
AU001, Brisbane
UA002, Kyiv
PH001, Mandaue City
BE002, Sint-Niklaas
RS004, Belgrade
CZ005, Prague
CZ001, Prague
CZ003, Prague
FR007, Angoulême
FI002, Turku
SE003, Malmo
FR003, Montpellier
RS002, Kragujevac
FR002, Dole
FR001, Orvault
UA003, Dnipro
LT002, Kaunas
MY002, Kuala Lumpur
MY003, Kuala Lumpur
FR005, Wattigny
CZ002, Brno
UA005, Kharkiv
UA001, Odesa
FR008, Rouen
CZ006, Sternberk
UA004, Lviv
LT003, Klaipėda
FR004, Savigny-sur-Orge
RU005, Arkhangelsk
RU002, Nikol'skoye
RU003, Saint Petersburg
RU004, Saratov
IN002, Pune
IN003, Mangalore
RU001, Tomsk
AT002, Vienna
AT003, Vienna
FI006, Järvenpää
FI004, Seinäjoki
FI005, Tampere
IN001, Ahmedabab
IN009, Ahmedabad
LT001, Vilnius
PH003, Mandaluyong
CA006, Mississauga
CA004, Oakville
CA003, Penticton
CA005, Toronto
CA001, Vancouver
CZ004, Prague
FI001, Helsinki
FI003, Helsinki
IN006, Hyderabaad
KR003, Gwangju
KR002, Seoul
KR001, Seoul
SE006, Halmstad
SE001, Linköping
SE002, Lund
SE005, Stockholm
SE004, Uppsala
H. Lundbeck A/S
INDUSTRY